NuVasive interbody line gets green light for sagittal deformity treatment

The FDA has cleared NuVasive’s thoracolumbar interbody portfolio for the treatment of multilevel sagittal deformities.

Advertisement

The interbody line was previously approved for one- to two-level spine surgery, according to a Nov. 4 announcement from the spine device company.

The portfolio features the company’s Cohere, Modulus, TLX, MLX and CoRoent implants, which are available in several dimensions to fit each patient’s unique anatomy.

The implants can be integrated with NuVasive’s Bendini spinal rod bending system and its surgical planning tools designed for improved sagittal alignment.

More articles on devices:
Robotics in spine surgery: 17 notes for surgeons, ASCs & administrators
Zimmer Biomet net sales increase 2%, knee sales dip .5% in Q3
10 most influential orthopedic specialists on Twitter in Q3, according to GlobalData

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.